CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of "Hold" by Brokerages

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) have earned a consensus recommendation of "Hold" from the seventeen brokerages that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $69.53.

A number of research firms have recently commented on CRSP. Wall Street Zen upgraded CRISPR Therapeutics to a "sell" rating in a research note on Friday, May 16th. JMP Securities reaffirmed a "market outperform" rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, May 21st. Chardan Capital reduced their price objective on CRISPR Therapeutics from $84.00 to $82.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. HC Wainwright reaffirmed a "buy" rating and set a $65.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, May 20th. Finally, Barclays reduced their price target on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating for the company in a report on Friday, May 9th.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,932 shares of the business's stock in a transaction dated Thursday, May 29th. The shares were sold at an average price of $35.94, for a total value of $141,316.08. Following the transaction, the insider now directly owns 6,068 shares in the company, valued at $218,083.92. The trade was a 39.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.10% of the stock is owned by insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of large investors have recently bought and sold shares of the business. Voya Investment Management LLC grew its holdings in shares of CRISPR Therapeutics by 60.2% during the first quarter. Voya Investment Management LLC now owns 13,870 shares of the company's stock worth $472,000 after purchasing an additional 5,210 shares during the last quarter. Bayforest Capital Ltd acquired a new position in CRISPR Therapeutics during the 1st quarter worth about $423,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in CRISPR Therapeutics by 182.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,952,751 shares of the company's stock worth $66,452,000 after acquiring an additional 1,262,560 shares during the last quarter. Woodline Partners LP increased its position in CRISPR Therapeutics by 34.3% in the 1st quarter. Woodline Partners LP now owns 136,483 shares of the company's stock valued at $4,645,000 after acquiring an additional 34,883 shares in the last quarter. Finally, Millennium Management LLC raised its stake in shares of CRISPR Therapeutics by 6,769.1% in the first quarter. Millennium Management LLC now owns 583,733 shares of the company's stock worth $19,864,000 after acquiring an additional 575,235 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Price Performance

Shares of CRSP stock traded up $1.23 during trading on Friday, reaching $46.78. The company had a trading volume of 2,454,414 shares, compared to its average volume of 1,785,659. The firm's 50 day simple moving average is $38.75 and its two-hundred day simple moving average is $40.49. CRISPR Therapeutics has a one year low of $30.04 and a one year high of $63.68. The company has a market capitalization of $4.04 billion, a PE ratio of -10.35 and a beta of 1.75.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 20.08% and a negative net margin of 1,023.64%. During the same quarter last year, the firm earned ($1.43) earnings per share. CRISPR Therapeutics's revenue was up 71.6% on a year-over-year basis. Analysts forecast that CRISPR Therapeutics will post -5.16 earnings per share for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.